Hosted on MSN
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...
DelveInsight's“ Marginal Zone Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results